Esomeprazole Magnesium and Sodium Bicarbonate Capsules(Xiamen Encheng Pharma)

Tier C — Watch / trade

Originator

2024

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：Proton pump

Indications (approved)：Gastric ulcer, Gastro-oesophageal reflux disease

Regional status

China

Approved

2024-05-08

Japan

Factories producing this API8

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

8 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Esomeprazole Magnesium and Sodium Bicarbonate Capsules(Xiamen Encheng Pharma)?

Approved indications include: Gastric ulcer, Gastro-oesophageal reflux disease.

When does the Esomeprazole Magnesium and Sodium Bicarbonate Capsules(Xiamen Encheng Pharma) patent expire?

No public expiry year is available for Esomeprazole Magnesium and Sodium Bicarbonate Capsules(Xiamen Encheng Pharma) yet; this page updates once verified.

How do I get a quote for Esomeprazole Magnesium and Sodium Bicarbonate Capsules(Xiamen Encheng Pharma) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27